Baillie Gifford & CO Alnylam Pharmaceuticals, Inc. Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
642Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$4.11 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.14 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.38 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.3 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.23 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...